Imagine a world where a single pill could revolutionize the way we tackle obesity, sparking both hope and heated debates. That’s exactly what’s happening with Novo Nordisk’s Wegovy pill, which sent the company’s shares soaring by 5% after a promising U.S. launch. But here’s where it gets controversial: while early prescription data looks encouraging, experts warn it’s too soon to crown this pill as the ultimate game-changer. Could this be the breakthrough millions have been waiting for, or is the hype premature? Let’s dive in.
Novo Nordisk’s Wegovy, the first-ever GLP-1 pill for obesity, hit the U.S. market on January 5th, 2026, following its approval in late December. The initial numbers are impressive: according to Leerink Partners analyst David Risinger, around 3,100 prescriptions were filled in the first week, citing IQVIA data. To put that in perspective, Eli Lilly’s popular obesity injection, Zepbound, saw roughly 1,300 prescriptions in its debut week back in late 2023. But here’s the twist: TD Cowen analysts report slightly higher figures, with around 4,290 prescriptions filled during Wegovy’s first full week, based on Symphony data via Bloomberg. Is this a sign of dominance, or just a fleeting trend?
And this is the part most people miss: these numbers might not tell the full story. TD Cowen notes that their data likely excludes prescriptions from Novo Nordisk’s direct-to-consumer pharmacy and telehealth partners, which could significantly boost the total. If accurate, the pill is already outpacing injectable alternatives at a similar stage—a bold claim that has investors and healthcare professionals alike taking notice.
But let’s not forget the competition. Eli Lilly, Novo Nordisk’s chief rival, is hot on their heels with its own oral obesity drug, orforglipron, set to launch in the coming months. While Wegovy has a head start, it comes with a catch: it’s a peptide medication requiring users to avoid food and drink for 30 minutes after taking it. Eli Lilly’s pill, on the other hand, is a small molecule drug with no such restrictions. Which approach will win over patients in the long run?
For Novo Nordisk, the stakes are high. After losing ground to Eli Lilly in the obesity and diabetes drug market in early 2025, the Danish drugmaker is banking on Wegovy to reclaim its share. The initial data is a morale boost, but analysts caution that sustained success will depend on more comprehensive data and how demand shifts once Eli Lilly’s pill enters the fray.
So, what do you think? Is Wegovy the future of obesity treatment, or will it face stiff competition from Eli Lilly’s more user-friendly option? And how much should we read into these early numbers? Let us know in the comments—this debate is just heating up!
